Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
110 hedge funds and large institutions have $326M invested in Achillion Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 22 closing their positions.
432% more call options, than puts
Call options by funds: $399K | Put options by funds: $75K
99% more capital invested
Capital invested by funds: $164M → $326M (+$162M)
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 121 → 110 (-11)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.15M |
| 2 |
Millennium Management
New York
|
+$7.53M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.83M |
| 4 |
MCO
MAK Capital One
New York
|
+$4.27M |
| 5 |
Goldman Sachs
New York
|
+$4.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.87M |
| 2 |
AC
Armistice Capital
New York
|
-$4.42M |
| 3 |
Two Sigma Investments
New York
|
-$2M |
| 4 |
Man Group
London,
United Kingdom
|
-$1.87M |
| 5 |
6CM
683 Capital Management
New York
|
-$1.59M |
ACHN Hedge Fund Activity: Q1 2019 in Review
110 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2019, worth a combined $326M — up 99% from $164M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACHN and 11 opened new positions — a net loss of 11 holders — while 33 trimmed existing stakes and 38 added.
The largest buyer was Vanguard Group, adding an estimated $8.15M. The largest seller was Citadel Advisors, cutting an estimated $5.87M.
- 110 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2019, down from 121 in Q4 2018.
- Funds reported $326M of Achillion Pharmaceuticals stock for Q1 2019, up 99% quarter-over-quarter.
- 11 funds opened new Achillion Pharmaceuticals positions in Q1 2019 and 22 closed out, a net change of -11 holders.
- The largest Achillion Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $8.15M added.
- The largest Achillion Pharmaceuticals seller in Q1 2019 was Citadel Advisors, an estimated $5.87M sold.
Based on aggregated 13F filings for Q1 2019.